Abivax (ABVX) Total Liabilities (2021 - 2026)

Abivax's Total Liabilities history runs 6 years deep, the most recent figure standing at $137.6 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 21.66% year-over-year to $137.6 million in Q1 2026; TTM through Mar 2026 was $137.6 million, a 21.66% decrease from a year earlier, with the FY2025 full-year figure at $150.3 million, down 15.65% from the prior year.
• Total Liabilities slipped to $137.6 million in Q1 2026 per ABVX's latest filing, from $150.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $762.3 million in Q3 2025 and bottomed at $16.6 million in Q4 2022.
• The 5-year median for Total Liabilities is $150.3 million (2025), against an average of $211.1 million.
• Across the five-year window, Total Liabilities jumped 337.71% in 2024 and tumbled 55.8% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $16.6 million in 2022, then surged by 142.51% to $40.2 million in 2023, then soared by 337.71% to $175.9 million in 2024, then retreated by 14.56% to $150.3 million in 2025, then decreased by 8.46% to $137.6 million in 2026.
• Per Business Quant, the three latest ABVX Total Liabilities figures stand at $137.6 million (Q1 2026), $150.3 million (Q4 2025), and $762.3 million (Q3 2025).